Bon Natural Life (BON) Competitors $1.38 -0.03 (-2.13%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.38 +0.01 (+0.36%) As of 07/25/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock BON vs. TRVN, PTPI, SRNE, PBLA, ZVSA, BPTSY, HEPA, VRPX, VIRX, and NCNAShould you be buying Bon Natural Life stock or one of its competitors? The main competitors of Bon Natural Life include Trevena (TRVN), Petros Pharmaceuticals (PTPI), Sorrento Therapeutics (SRNE), Panbela Therapeutics (PBLA), ZyVersa Therapeutics (ZVSA), Biophytis (BPTSY), Hepion Pharmaceuticals (HEPA), Virpax Pharmaceuticals (VRPX), Viracta Therapeutics (VIRX), and NuCana (NCNA). These companies are all part of the "pharmaceutical products" industry. Bon Natural Life vs. Its Competitors Trevena Petros Pharmaceuticals Sorrento Therapeutics Panbela Therapeutics ZyVersa Therapeutics Biophytis Hepion Pharmaceuticals Virpax Pharmaceuticals Viracta Therapeutics NuCana Trevena (NASDAQ:TRVN) and Bon Natural Life (NYSE:BON) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment. Does the media favor TRVN or BON? In the previous week, Bon Natural Life had 4 more articles in the media than Trevena. MarketBeat recorded 4 mentions for Bon Natural Life and 0 mentions for Trevena. Bon Natural Life's average media sentiment score of 0.67 beat Trevena's score of 0.00 indicating that Bon Natural Life is being referred to more favorably in the news media. Company Overall Sentiment Trevena Neutral Bon Natural Life Positive Which has preferable valuation & earnings, TRVN or BON? Bon Natural Life has higher revenue and earnings than Trevena. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrevena$443K1.97-$40.29M-$47.04-0.02Bon Natural Life$23.84M0.01$400KN/AN/A Which has more risk & volatility, TRVN or BON? Trevena has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Bon Natural Life has a beta of -0.49, meaning that its stock price is 149% less volatile than the S&P 500. Is TRVN or BON more profitable? Company Net Margins Return on Equity Return on Assets TrevenaN/A N/A -119.55% Bon Natural Life N/A N/A N/A Do analysts prefer TRVN or BON? Trevena currently has a consensus target price of $5.00, indicating a potential upside of 449.45%. Given Trevena's stronger consensus rating and higher probable upside, equities analysts plainly believe Trevena is more favorable than Bon Natural Life.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevena 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Bon Natural Life 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of TRVN or BON? 13.6% of Trevena shares are owned by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are owned by institutional investors. 2.7% of Trevena shares are owned by insiders. Comparatively, 26.5% of Bon Natural Life shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryBon Natural Life beats Trevena on 6 of the 11 factors compared between the two stocks. Get Bon Natural Life News Delivered to You Automatically Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BON vs. The Competition Export to ExcelMetricBon Natural LifeMedicinals & botanicals IndustryDiscretionary SectorNYSE ExchangeMarket Cap$230K$3.44B$8.32B$21.18BDividend YieldN/AN/A3.10%3.59%P/E RatioN/A7.6521.5728.42Price / Sales0.0127.094.6860.33Price / Cash0.785.6214.6918.21Price / Book0.041.114.774.69Net Income$400K$17.44M$218.10M$993.25M7 Day Performance-2.13%2.77%2.27%1.65%1 Month Performance9.52%9.37%43.94%4.44%1 Year Performance-97.32%-27.73%16.36%9.99% Bon Natural Life Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BONBon Natural LifeN/A$1.38-2.1%N/A-97.3%$230K$23.84M0.00100TRVNTrevena1.1372 of 5 stars$0.91flat$5.00+449.5%-83.9%$873K$443K-0.0240PTPIPetros PharmaceuticalsN/A$0.03-2.8%N/A-99.7%$872K$5.11M-0.0120Gap DownSRNESorrento Therapeutics0.476 of 5 stars$0.00-12.5%N/A-85.3%$772K$60.32M0.00800Gap DownPBLAPanbela Therapeutics0.2777 of 5 stars$0.16-1.3%N/A-53.3%$767KN/A0.006ZVSAZyVersa Therapeutics0.1938 of 5 stars$0.14-1.7%N/A-93.0%$685KN/A0.002Gap UpBPTSYBiophytisN/A$1.81flatN/AN/A$634KN/A0.0030HEPAHepion Pharmaceuticals0.1251 of 5 stars$0.06+32.4%N/A-99.9%$612KN/A-0.0120Gap UpHigh Trading VolumeVRPXVirpax PharmaceuticalsN/A$0.33-17.5%N/A-99.9%$410KN/A0.007Gap DownVIRXViracta Therapeutics2.5387 of 5 stars$0.01flat$1.75+17,793.7%N/A$389KN/A-0.0120NCNANuCana3.2569 of 5 stars$0.05+6.9%$25.00+48,919.6%-98.4%$290KN/A-0.0130News CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies Trevena Competitors Petros Pharmaceuticals Competitors Sorrento Therapeutics Competitors Panbela Therapeutics Competitors ZyVersa Therapeutics Competitors Biophytis Competitors Hepion Pharmaceuticals Competitors Virpax Pharmaceuticals Competitors Viracta Therapeutics Competitors NuCana Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BON) was last updated on 7/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredThe big winner of Crypto week?It’s Crypto Week at the White House — and the sector is moving from fringe to full-scale adoption. With Bit...Weiss Ratings | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bon Natural Life Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bon Natural Life With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
